Related Experiment Video

Updated: Jun 26, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

B Corkery1, J Crown, M Clynes

  • 1National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|January 20, 2009
PubMed
Abstract

Insights

Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, enhances chemotherapy response in triple-negative breast cancer (TNBC) cells. Combining gefitinib with carboplatin and docetaxel shows synergistic effects, warranting further investigation for TNBC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapy options.
  • Epidermal growth factor receptor (EGFR) is overexpressed in TNBC.
  • Investigating EGFR antagonists in TNBC is crucial.

Purpose of the Study:

  • To evaluate EGFR inhibitor activity alone and with chemotherapy in TNBC.
  • To assess gefitinib's effects on EGFR signaling and cell cycle.
  • To determine the synergistic potential of gefitinib with carboplatin and docetaxel.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) for EGFR and phosphorylated EGFR.
  • Chemotherapy sensitivity assays with EGFR inhibitors.
  • Analysis of gefitinib's impact on MAPK, Akt, and cell cycle progression.

Main Results:

  • TNBC cells overexpress EGFR compared to HER-2-positive cells.
  • Gefitinib blocked EGFR phosphorylation but showed less sensitivity in TNBC.
  • Gefitinib enhanced responses to carboplatin and docetaxel, with synergistic effects in combination.

Conclusions:

  • Gefitinib enhances chemotherapy efficacy in TNBC despite lower intrinsic sensitivity.
  • The combination of gefitinib, carboplatin, and docetaxel demonstrates significant synergy.
  • Further clinical investigation of this triple combination for TNBC is recommended.

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...